Ewing et al. showed that the use of abatacept prevented CD4+ cell activation and reduced atherosclerosis development in murine femoral arteries by 78%, whereas the administration of CTLA-4 blocking antibodies increased atherosclerotic lesion sizes [60]. Here, CTLA4 is linked to atherosclerosis.